OneMedNet Corp

Overview

Compare with iSpecimen Inc., Absci Corp or VITASPRING BIOMEDICAL CO. LTD., or pick any stock.

• TickerONMD on Nasdaq¹
• IndustryServices-Commercial Physical & Biological Research¹
• HeadquartersSurrey, United Kingdom¹
• Incorporated inDE²
• Business addressTrident Court, 1 Oakcroft Road, Chessington, Surrey, X0 Kt9 1Bd²
• Filer category, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

For this reason, the Food and Drug Administration (“FDA”) has instituted Real World Data guidelines for regulatory approvals.³ From its latest annual report

Corporate structure

OneMedNet Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What OneMedNet Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

Our corporate headquarters in Eden Prairie, Minnesota is leased on a month-to-month basis. We have a remote work policy that allows all employees to be remote on an ongoing basis. As a result, our employees are in permanent remote status and are not required to report to an office for work. We believe our current office space is adequate for our current operations and our anticipated future needs.

Item 2 of the 10-K filed Mar 30, 2026.³

Leadership

Who has led OneMedNet Corp, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerAaron Green Nov 26, 2025 to now¹⁰
• Chief executive officerPaul Casey Nov 15, 2023 to Nov 15, 2023¹¹
• Chief executive officerBarry James Anderson May 13, 2021 to May 13, 2021¹²
• Chief financial officerRobert Lawrence Golden Nov 26, 2025 to now¹³
• Chief financial officerFirdauz Mokhtar May 7, 2021 to May 7, 2021¹⁴

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerLisa Embree named Aug 2, 2024²⁵
• DirectorErkan Akyuz named Apr 12, 2024 to Aug 2, 2024²⁵

Former names

• Data Knights Acquisition Corp.Mar 9, 2021 to Nov 7, 2023²

Timeline

1. Oct 14, 20268-K Other events²⁶
2. Sep 29, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed²⁷
3. Sep 23, 20268-K Executive or director change; Shareholder vote²⁸
4. Jul 24, 20268-K Director nominations; Other events²⁹
5. Jul 1, 20268-K Entered a material agreement³⁰
6. Apr 20, 20268-K Listing notice or transfer³¹
7. Dec 23, 20258-K Shareholder vote; Other events³²
8. Nov 26, 2025New chief executive Aaron Green becomes CEO¹⁰
9. Nov 7, 20258-K Executive or director change³³
10. Oct 9, 20258-K Other events³⁴
11. Sep 15, 20258-K Other events³⁵
12. Jul 11, 20258-K Regulation FD disclosure³⁶
13. Jul 8, 20258-K Regulation FD disclosure³⁷
14. Nov 15, 2023New chief executive Paul Casey becomes CEO¹¹
15. May 13, 2021New chief executive Barry James Anderson becomes CEO¹²

Calendar

Coming up

1. Nov 13, 2026Reports results for the quarter ending Sep/2026³⁸

When it reported results

1. May 23, 2024Reported quarterly or annual results³⁹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

258 filings to the SEC since October 2021: 7 annual reports, 16 quarterly reports, 66 major events, 41 insider forms, 22 large holders, 2 private raises, 104 other. The latest 20:

1. Oct 14, 20268-K EDGAR
2. Oct 13, 20264 EDGAR
3. Oct 13, 20264 EDGAR
4. Oct 9, 20264 EDGAR
5. Oct 9, 20264 EDGAR
6. Sep 30, 2026424B3 EDGAR
7. Sep 30, 2026424B3 EDGAR
8. Sep 29, 20268-K EDGAR
9. Sep 23, 20268-K EDGAR
10. Sep 14, 20264 EDGAR
11. Aug 20, 2026424B3 EDGAR
12. Aug 20, 2026424B3 EDGAR
13. Aug 19, 2026DEF 14A EDGAR
14. Aug 14, 202610-Q EDGAR
15. Aug 7, 20264 EDGAR
16. Aug 7, 2026PRE 14A EDGAR
17. Jul 24, 20268-K EDGAR
18. Jul 13, 2026424B3 EDGAR
19. Jul 10, 2026EFFECT EDGAR
20. Jul 8, 2026S-1/A EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

89 open-market trades by officers, directors and large owners since October 2021: 86 buys and 3 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• DISCOVERY CAPITAL MANAGEMENT, LLC / CTSCHEDULE 13G/A, 2 filings Aug 5, 2024 to Nov 14, 2025⁴⁰
• TD SECURITIES (USA) LLCSCHEDULE 13G/A, 2 filings Feb 14, 2025 to Nov 14, 2025⁴¹
• COWEN AND COMPANY, LLCSC 13G, 1 filing Nov 12, 2024⁴²
• Off the Chain Capital, LLCSC 13G, 1 filing Oct 1, 2024⁴³
• Westchester Capital Management, LLCSC 13G/A, 2 filings Feb 14, 2023 to Feb 14, 2024⁴⁴
• Owl Creek Asset Management, L.P.SC 13G/A, 2 filings Apr 11, 2023 to Feb 5, 2024⁴⁵
• Shaolin Capital Management LLCSC 13G/A, 2 filings Feb 11, 2022 to Feb 23, 2023⁴⁶
• ATW SPAC MANAGEMENT LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023⁴⁷
• BOOTHBAY FUND MANAGEMENT, LLCSC 13G/A, 1 filing Feb 14, 2023⁴⁸
• Karpus Management, Inc.SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023⁴⁹
• Saba Capital Management, L.P.SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023⁵⁰
• Hudson Bay Capital Management LPSC 13G/A, 2 filings Feb 7, 2022 to Feb 7, 2023⁵¹
• Space Summit Capital LLCSC 13G/A, 1 filing Feb 3, 2022⁵²

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Jul 23, 2024Raised $4.6 million in a private offering of equity Form D: 2 investors so far Form D
2. Mar 28, 2024Raised $4.5 million in a private offering of debt Form D: $5 million offered in all Form D

SEC filer profile

How OneMedNet Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGAROneMedNet Corp¹
• CIK0001849380
• Employer ID (EIN)86-2076743³
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)8731 Services-Commercial Physical & Biological Research¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business addressTrident Court, 1 Oakcroft Road, Chessington, Surrey, X0 KT9 1BD¹
• Phone011-44-208-090-2009¹
• Shares outstanding59,286,450 as of Aug 11, 2026⁸
• Public float$13.8M as of Jun 30, 2025³
• AuditorWithumSmith+Brown, PC, East Brunswick, New Jersey PCAOB ID 100; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceMar 9, 2021¹
• Filings289 in all: 8-K (68), 4 (28), 425 (19), 3 (18), 10-Q (17), CORRESP (17), SC 13G (13), UPLOAD (13)¹
  All 35 form types

  SC 13G/A (12), 424B3 (11), S-4/A (10), S-1/A (9), 10-K (5), DEF 14A (5), NT 10-Q (5), EFFECT (4), PRE 14A (4), NT 10-K (3), PRER14A (3), S-1 (3), 10-K/A (2), 10-Q/A (2), 424B4 (2), D (2), DEFA14A (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 25-NSE (1), 3/A (1), 8-A12B (1), 8-K/A (1), CERT (1), S-4 (1), S-8 (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Mar 30, 2026
  Quarterly report (10-Q) Aug 14, 2026
  Proxy statement (DEF 14A) Aug 19, 2026
  Latest 8-K (8-K) Oct 14, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks OneMedNet Corp names in Item 1A of its 10-K filed Mar 30, 2026: 28 risks under these headings, as written.³

• Risks Related to Our Business
• We have a history of operating losses and may never achieve profitability in the future.
• The report of our independent registered public accounting firm for the fiscal years ended December 31, 2025 and 2024 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
• We may encounter difficulties in managing our attempted growth of our business, which could negatively impact our operations.
• We may be unable to execute our business objectives and growth strategies successfully or sustain our growth and, as a result, this could have a material adverse effect on our operating results.
• The Real World Data and Real World Evidence business market continues to evolve and is highly competitive, and we may not be successful in competing in this industry or establishing and maintaining confidence in our long-term business prospects among current and future partners and customers.
• If we are unable to attract and retain key employees and qualified personnel, our ability to compete could be harmed.
• A material breach in security relating to the Company’s information systems and regulation related to such breaches, cyber-attacks, or other disruptions could adversely affect the Company, expose us to liability and affect our business and reputation.
• If we are unable to adequately protect or expand our intellectual property related to our current or future products, our business prospects could be harmed.
• If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.
• Our collection, use, and disclosure of personal information is subject to U.S. state and federal privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm.
• Our operations could be damaged or adversely affected as a result of natural disasters and other catastrophic events.

Legal proceedings

We may be subject from time to time to various claims, lawsuits and other legal and administrative proceedings arising in the ordinary course of business. Some of these claims, lawsuits and other proceedings may involve highly complex issues that are subject to substantial uncertainties, and could result in damages, fines, penalties, non-monetary sanctions or relief. A discussion of legal matters is found in Note 13 — Commitments and Contingencies in the accompanying notes to the consolidated financial statements included in Part II - Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.

The opening of Item 3, Legal Proceedings.³